跳到正文
EMA QWP 药品质量问答·AI 评分58

EMA QWP 更新兽药 F.II.b.1 与 F.II.b.4 复杂生产工艺问答

EMA QWP:Complex manufacturing processes in F.II.b.1 and F.II.b.4 (veterinary)

AI 导读

EMA QWP 更新兽药质量问答,明确变更分类 F.II.b.1(生产场地替换或增加)和 F.II.b.4(成品批量变更)中复杂生产工艺的判定口径并给出示例。问答指出并非所有非标准工艺在此语境下都属复杂工艺,无菌工艺不属复杂工艺,但作为非标准工艺仍需提交生产规模工艺验证数据。按 VRA-R 提交的申请人须说明工艺不属于复杂的理由,理由未被接受时主管机构可要求撤回并按 VRA-S 重新提交。

正文 · 原文

EMA QWP 药品质量问答,第 1 部分。

官方章节更新记录:2026-03-02。

H 表示人用药,V 表示兽药;各问答的适用范围保留在原文中。

Complex manufacturing processes in F.II.b.1 and F.II.b.4 (veterinary)

1. What is understood by ‘manufactured by complex manufacturing processes’ in change category F.II.b.4 (change in batch size of the finished product) or in change category F.II.b.1 (replacement or addition of manufacturing site)? V Rev March 2026

In categories F.II.b.1 and F.II.b.4, a "complex manufacturing process" refers to situations where the manufacturing process involves complex technology that may present challenges during site transfer and/or scale-up activities that could impact the quality of the finished product and therefore require submission of variation requiring assessment with a standard timetable (VRA-S).

It should be noted that not all non-standard processes (as defined in Annex II of the Guideline on process validation for finished products - information and data to be provided in regulatory submissions) are considered complex in this context.

For example, ‘aseptic processing’ is not a complex manufacturing process for the purpose of classifications of changes in categories F.II.b.1 and F.II.b.4, but as it is a non-standard manufacturing process, production scale process validation data is required.

Therefore, to help the interpretation of the term "complex manufacturing process" in the categories F.II.b.1 and F.II.b.4, some examples of products manufactured by processes that could be considered complex are provided below (but are not limited to):

  • Liposomal preparations
  • Nanoparticulate preparations (e.g. Lipid nanoparticles)
  • Parenteral modified release preparations
  • Metered-dose preparations for inhalation and inhalation powders
  • Multilayer tablets

If a change is submitted as a VRA with reduced timetable (VRA-R), applicants must provide a justification if they consider that the manufacturing process is not "complex”, as per the above interpretation. If the justification is not accepted, the competent authority may ask the applicant to withdraw and resubmit as VRA-S variation. Appropriate variation categorisation can also be anticipated using Post Approval Change Management Protocols. If there is any uncertainty, applicants may consult the relevant authority before submitting the variation.

来源:EMA QWP 药品质量问答 · ema.europa.eu